Loading...
01/11 07:35
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals a mixed picture. Basic financial performance shows improvement with a net income for H1 2025, but the Q2 2025 net loss and decreased cash position are concerns. Product development is promising with Symvess launch and ongoing trials, but pricing adjustments may impact margins. Market strategy is sound, targeting military and civilian markets. However, the Q&A section highlights uncertainties in reimbursement and trial timelines. Overall, the mixed signals and lack of clear guidance suggest a neutral stock price movement in the short term.
Revenue for Q2 2025 $0.3 million, with $0.1 million from U.S. sales of Symvess and $0.2 million from a research collaboration. There was no revenue in Q2 2024. The increase is due to the commercial launch of Symvess and the research collaboration.
Revenue for the first half of 2025 $0.8 million, with $0.2 million from U.S. sales of Symvess and $0.6 million from the research collaboration. There was no revenue in the first half of 2024. The increase is attributed to the same reasons as Q2 2025.
Cost of Goods Sold (COGS) for Q2 2025 $0.2 million, compared to $0 in Q2 2024. The increase is due to overhead related to unused production capacity.
Cost of Goods Sold (COGS) for the first half of 2025 $0.4 million, compared to $0 in the first half of 2024. The increase is due to the same reasons as Q2 2025.
Research and Development (R&D) expenses for Q2 2025 $22.0 million, compared to $23.8 million in Q2 2024. The decrease is primarily due to capitalization of overhead costs associated with the commercial manufacturing of Symvess, offset by higher noncommercial production runs.
Research and Development (R&D) expenses for the first half of 2025 $37.4 million, compared to $45.0 million in the first half of 2024. The decrease is due to decreased material costs and capitalization of expenditures for inventory following the commercial launch of Symvess.
Selling, General, and Administrative (SG&A) expenses for Q2 2025 $7.8 million, compared to $5.7 million in Q2 2024. The increase is primarily due to the U.S. commercial launch of Symvess, including increased personnel expenses.
Selling, General, and Administrative (SG&A) expenses for the first half of 2025 $15.9 million, compared to $11.1 million in the first half of 2024. The increase is due to the same reasons as Q2 2025.
Net loss for Q2 2025 $37.7 million, compared to $56.7 million in Q2 2024. The decrease is primarily due to the noncash remeasurement of the contingent earn-out liability.
Net income for the first half of 2025 $1.5 million, compared to a net loss of $88.6 million in the first half of 2024. The improvement is primarily due to the noncash remeasurement of the contingent earn-out liability.
Cash, cash equivalents, and restricted cash as of June 30, 2025 $88.4 million. Total cash used was $6.9 million for the first half of 2025, compared to net cash provided of $13.1 million in the first half of 2024. The change is due to differences in proceeds from public offerings and loan arrangements between the two periods.
Symvess FDA approval and launch: Symvess received FDA approval for extremity vascular trauma treatment and is being commercially launched. 82 civilian hospitals are now eligible to purchase Symvess, up from 5 previously. Additionally, Symvess received ECAT listing approval, enabling sales to military and VA facilities.
ATEV pipeline progress: The acellular tissue engineered vessel (ATEV) program is advancing, with promising results from the V007 Phase III trial for dialysis access in high-risk patients. Plans are underway for a supplemental BLA filing in 2026.
Market expansion for Symvess: Symvess is now available to 82 civilian hospitals and 35 military treatment facilities, along with 160 VA hospitals. The product has also recorded its first sale to a U.S. military facility.
Cost reduction measures: The company reduced its workforce by 30 employees and deferred new hires, saving an estimated $50 million over 2025 and 2026.
Revenue and sales: Q2 2025 revenue was $0.3 million, with $0.1 million from Symvess sales. July sales of $0.3 million exceeded total sales for the first half of the year.
Focus on high-risk dialysis patients: The company is targeting high-risk dialysis patients for ATEV, addressing unmet needs in this population.
Private payer engagement: Discussions with private payers are ongoing to secure supplemental reimbursement for Symvess, following CMS's NTAP denial.
Unsubstantiated Public Attacks: The company faced headwinds in April and May due to unsubstantiated public attacks by certain detractors, which could have impacted its reputation and slowed commercial progress.
CMS NTAP Reimbursement Denial: The Centers for Medicare and Medicaid Services (CMS) declined the company's application for the new technology add-on payment (NTAP) for Symvess, citing lack of a unique mechanism of action. This could limit reimbursement options and affect adoption rates in certain patient populations.
Workforce Reduction: The company implemented a workforce reduction plan, cutting 30 employees and deferring new hires to extend its cash runway. While this reduces costs, it may strain resources and impact operational efficiency.
High R&D and SG&A Expenses: Research and development expenses remain high at $22 million for Q2 2025, and selling, general, and administrative expenses increased to $7.8 million, driven by the commercial launch of Symvess. These costs could pressure financial performance if revenue growth does not accelerate.
Limited Revenue Growth: Revenue for Q2 2025 was $0.3 million, with only $0.1 million from U.S. sales of Symvess. This limited revenue growth may challenge the company's ability to sustain operations and fund future initiatives.
Dependence on Private Payers: The company is heavily reliant on private payers for reimbursement of Symvess, as Medicare covers only 4.3% of vascular trauma patients. This dependence could pose risks if private payers do not provide adequate reimbursement.
Production Overhead Costs: Cost of goods sold included overhead related to unused production capacity, which was recorded as an expense. This indicates inefficiencies in scaling production to meet demand.
Commercial Expansion of Symvess: The company expects the number of hospitals eligible to purchase Symvess to grow beyond the current 82 civilian hospitals and 35 military treatment facilities. An additional 40 VAC sites are currently reviewing Symvess, and the company anticipates further expansion in the near future.
Sales Growth: July product sales of $0.3 million exceeded total sales for the first half of the year. The company expects continued sales growth driven by increased hospital approvals and military facility adoption.
Supplemental BLA Filing for Dialysis Access: The company plans to file a supplemental BLA for dialysis access in the second half of 2026, targeting patients at high risk of fistula nonmaturation. This will include data from the V012 and V007 Phase III pivotal studies.
V012 Phase III Trial Progress: The ongoing V012 Phase III trial for dialysis access has enrolled 100 out of 150 target patients. An interim analysis is planned for the first 80 patients with one year of follow-up, achieved in April 2025. Results will inform the supplemental BLA filing.
Market Targeting for Dialysis Access: The company is focusing on patients with high unmet medical needs, particularly those at high risk of fistula nonmaturation, which represents a significant portion of the dialysis access market.
Cost Reduction and Financial Savings: The company expects net savings of approximately $3.8 million in 2025 and up to $38 million in 2026 due to workforce reductions and operating cost reductions, totaling over $50 million in savings for 2025 and 2026.
The selected topic was not discussed during the call.
The earnings call presents a positive outlook with strong financial improvements, reduced net loss, and promising trial data for Symvess, which is expected to drive future growth. The Q&A section highlights positive feedback from hospitals and surgeons, successful cost-saving measures, and strategic expansion plans. Despite some unclear responses, the overall sentiment is optimistic, supported by strong data and strategic initiatives, likely leading to a positive stock price movement.
The earnings call reveals a mixed picture. Basic financial performance shows improvement with a net income for H1 2025, but the Q2 2025 net loss and decreased cash position are concerns. Product development is promising with Symvess launch and ongoing trials, but pricing adjustments may impact margins. Market strategy is sound, targeting military and civilian markets. However, the Q&A section highlights uncertainties in reimbursement and trial timelines. Overall, the mixed signals and lack of clear guidance suggest a neutral stock price movement in the short term.
The earnings call reveals strong financial performance, with EPS and revenue exceeding expectations. Although there are supply chain challenges and workforce reductions, the company has managed to reduce net losses and increase cash reserves. The launch of Symvess is progressing, and partnerships, such as with Fresenius, remain strong. Despite some concerns raised during the Q&A, overall sentiment is positive, especially with significant cost savings and a strong cash position. The stock is likely to react positively, potentially within the 2% to 8% range.
The earnings call presents a mixed picture. Financial performance shows a positive net income due to non-cash adjustments, yet revenue is low, raising concerns about future growth. Product development and market strategy are progressing, but initial sales are slow. The Q&A reveals ongoing challenges with VAC approvals and military hospital processes. Despite cost savings and a strong cash position, the public offering and workforce reductions may worry investors. The lack of a clear timeline for military hospital adoption and vague management responses contribute to uncertainty. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
